[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"premedication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:premedication":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,72,101,140,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100624472","comparative-assessment-of-oral-premedication-regimens-in-pediatric-ambulatory-surgery-100624472",false,"NCT07410078","Comparative Assessment of Oral Premedication Regimens in Pediatric Ambulatory Surgery","A Comparative Evaluation of Oral Premedication Regimens in Pediatric Patients Undergoing Ambulatory Surgery","Inclusion Criteria:\n\n* Pediatric patients aged 4-12 years\n* American Society of Anesthesiologists (ASA) physical status I-II\n* Scheduled for elective ambulatory (day-case) surgery\n* Eligible to receive oral premedication\n* Cognitive ability sufficient to complete behavioral and pain scale assessments\n* Written informed consent obtained from a parent or legal guardian\n\nExclusion Criteria:\n\n* ASA physical status III or higher\n* Moderate to severe intellectual disability\n* Moderate to severe autism spectrum disorder\n* Known allergy or contraindication to midazolam, ketamine, or ibuprofen\n* History of sedative or opioid use within the previous 24 hours\n* Complete loss of premedication due to vomiting","ALL","4 Years","12 Years",{"count":20,"type":21},135,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective, three-arm study aims to evaluate the effects of different oral premedication regimens on venipuncture tolerance in pediatric patients undergoing ambulatory surgery. Children aged 4-12 years scheduled for elective day-case procedures will receive oral midazolam alone, midazolam combined with ibuprofen, or midazolam combined with ketamine prior to anesthesia induction. The primary outcome is the proportion of children with well-tolerated venipuncture, assessed using standardized behavioral and pain scales. Secondary outcomes include anxiety levels, venipuncture success parameters, time to successful intravenous access, and parent and anesthesiologist satisfaction. In cases of inadequate premedication or failed venipuncture, a predefined rescue inhalational induction protocol will be applied to ensure patient safety. The study aims to identify clinically effective premedication strategies that may improve cooperation and reduce distress during intravenous cannulation in pediatric ambulatory anesthesia.",[27,28],"Pediatric Anesthesia","Premedication",[27,28,30,31,32],"Ambulatory surgery","Venipuncture tolerance","Anxiety","NOT_YET_RECRUITING","2026-03-03",{"date":36,"type":37},"2026-03-05","ACTUAL",{"date":39,"type":21},"2026-02-19",{"date":41,"type":21},"2026-09-01",{"name":43,"class":44},"Diskapi Yildirim Beyazit Education and Research Hospital","OTHER_GOV",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100627578","effect-of-virtual-reality-on-the-need-of-premedication-before-surgery-100627578","NCT07450456","Effect of Virtual Reality on the Need of Premedication Before Surgery","Effect of Virtual Reality Immersion on the Need of Pharmacological Premedication Before Cardiac Surgery","Inclusion Criteria:\n\n* All patients undergoing elective surgery\n* Minimal age of 18-year-old\n* Able to give informed consent for the study\n* Requesting pharmacological premedication in the pre-operative period.\n\nExclusion Criteria:\n\n* Lacking capacity or ability to complete the consent form or to respond to the required obligations linked to the study protocol\n* Contraindications to pharmacological premedication\n* Known cognitive dysfunction, previous history of neurological\u002Fpsychiatric diseases like epilepsy\n* Non Italian speaking patients\n* Injuries to the head\u002Fface that would prohibit wearing headsets\n* Infectious skin conditions of the head\u002Fface\n* Contact isolation due to bacteria and viruses\n* Symptoms of vertigo or motion sickness\n* Reduced visual or auditory acuity\n* Pregnancy\n* Claustrophobia","18 Years",{"count":55,"type":21},40,[24],"This study will assess, on patients requesting a pharmacological premedication in the preoperative period, if virtual reality reality could reduce the request of pharmacological premedication while maintaining a good level of comfort for the patient. The aim of this study is to understand if virtual reality could reduce the need for pharmacological premedication and their associated secondary effects.",[32,28,59,60],"Surgery","Virtual Reality","RECRUITING","2026-02-27",{"date":64,"type":37},"2026-03-04",{"date":66,"type":37},"2025-11-11",{"date":68,"type":21},"2026-10",{"name":70,"class":71},"Ente Ospedaliero Cantonale, Bellinzona","OTHER",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100613565","1-hour-premedication-for-allergy-goal-in-emergency-page-1-study-100613565","NCT07268248","1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study","1-hour Premedication for Allergy Goal in Emergency Computed Tomography, A Randomized Controlled Non-inferiority Trial: PAGE-1 Study","PAGE1","Inclusion Criteria:\n\n1. Adult (≥ 21 years old)\n2. Documented iodinated contrast allergy in the electronic health record\n3. CT with iodinated contrast ordered for a high-risk indication, † defined as post-arrest, concern for aortic dissection, ischemia, occlusion, obstruction, or other life-threatening conditions requiring timely diagnosis\n4. Willing and able to give consent\n\nExclusion Criteria:\n\n1. Previous enrollment in this study\n2. Pregnancy\n3. Seafood or iodine allergy, alone\n4. Gadolinium allergy","21 Years",{"count":82,"type":21},540,[24],"1-hour Premedication for Allergy Goal in Emergency: PAGE-1 is a prospective, parallel, two-arm, non-inferiority, randomized controlled trial evaluating the safety of a 1-hour (intervention) versus a 4-hour (standard regimen) intravenous (IV) premedication protocol in adult patients in the Emergency Department (ED) with a documented iodinated contrast allergy and requiring computed tomography (CT) imaging for a high-risk indication.",[86,87,88,28],"Allergic Reaction to Contrast Media","Hypersensitivity Reaction","Computed Tomography",[90,91,92],"Iodinated Contrast Reaction","Contrast-enhanced CT","Glucocorticoid prophylaxis","2026-02-16",{"date":39,"type":37},{"date":96,"type":21},"2026-06",{"date":98,"type":21},"2028-06",{"name":100,"class":71},"Paul Peng, MD PhD MSCR",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":16,"minAge":53,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":115,"conditions":116,"keywords":126,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100611785","phase-2-premedication-with-n-acetylcysteine-and-simethicone-to-improve-mucosal-visualization-in-elective-upper-endoscopy-100611785","NCT07245095","Premedication With N-acetylcysteine and Simethicone to Improve Mucosal Visualization in Elective Upper Endoscopy","Randomized Controlled Trial to Evaluate the Effect of Premedication With N-acetylcysteine and Simethicone on Mucosal Visibility During Elective Upper Gastrointestinal Endoscopy Using the TUGS Score","NACSIMET","Inclusion Criteria:\n\n* Men and women aged 18 to 70 years old.\n* Patients who agree to participate in the clinical trial.\n* Patients without active gastrointestinal bleeding.\n* Signing of informed consent form.\n\nExclusion Criteria:\n\n* Patients with a history of hypersensitivity to N-acetylcysteine\n* Patients with a history of hypersensitivity to simethicone\n* Patients with a previous endoscopic diagnosis\n* Patients with a history of gastric or bariatric surgery\n* Patients with a history of motor disorders (e.g., scleroderma, diabetic gastroparesis)\n* Patients taking medications that delay gastric emptying (GLP-1 analogues)\n* Pregnant or breastfeeding patients\n* Patients who do not agree to participate in the clinical trial",true,"99 Years",{"count":112,"type":21},132,[114],"PHASE2","The goal of this randomized, double-blind, placebo-controlled clinical trial is to assess whether the combination of N-acetylcysteine and simethicone improves mucosal visibility during upper gastrointestinal endoscopy in adults aged 18 to 99 years of both sexes, including both healthy individuals and those with non-bleeding gastrointestinal symptoms.\n\nThe main questions this study aims to answer are:\n\nDoes pre-endoscopy administration of N-acetylcysteine\u002Fsimethicone improve mucosal visualization based on the Toronto Upper Gastrointestinal Cleanliness Score (TUGS)?\n\nIs this combination safe and well tolerated in this patient population?\n\nResearchers will compare patients receiving N-acetylcysteine (600 mg) and simethicone (100 mg) orally 20-60 minutes before the procedure with those receiving placebo (water) to determine if there is a significant improvement in TUGS scores.\n\nParticipants will:\n\nReceive a single oral dose of either N-acetylcysteine\u002Fsimethicone or placebo prior to endoscopy\n\nUndergo a routine upper GI endoscopy\n\nHave mucosal cleanliness evaluated using the TUGS scoring system\n\nBe monitored for any adverse events or intolerance",[117,118,119,28,120,121,122,123,124,125],"Esophagogastroduodenoscopy","Simethicone","N-Acetylcysteine","Visualization","Esophagogastroduodensocopy (EGD) Procedure","Placebo - Control","Gastritis Associated With Helicobacter Pylori","Tumor Gastric","Lesions in the Esophagus, Stomach, Duodenum or Rectum",[117,127,28,118,128,129],"Mucous Membrane","Acetylcysteine","Gastrointestinal Tract","2025-11-20",{"date":132,"type":37},"2025-11-24",{"date":134,"type":37},"2025-09-12",{"date":136,"type":21},"2026-12-31",{"name":138,"class":71},"Hospital General de Mexicali",2,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":45},"100596793","anxiolytic-effect-of-virtual-reality-immersion-versus-midazolam-premedication-in-patients-undergoing-dacryocystorhinostomy-surgery-100596793","NCT07050095","Anxiolytic Effect of Virtual Reality Immersion Versus Midazolam Premedication in Patients Undergoing Dacryocystorhinostomy Surgery","Randomized Clinical Trial for Comparison Between the Anxiolytic Effect of Virtual Reality Immersion Versus Midazolam Premedication in Patients Undergoing Dacryocystorhinostomy Surgery","Inclusion Criteria:\n\n* Aged 18-65.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) classification: I - II.\n* Patient undergoing Dacryocystorhinostomy Surgery (DCR) operation under general anesthesia.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Patients with cardiac diseases.\n* Patients with renal diseases.\n* Patients with drug sensitivity and seizures.\n* Substance abuse and addiction.\n* Claustrophobia.\n* Patients with cerebrovascular disease.\n* Psychiatric and cognitive disorder.\n* Patients with severe teary eyes and blurring of vision.\n* Patients who express discomfort during the test.","65 Years",{"count":55,"type":21},[24],"The aim is to investigate the anxiolytic effect, and hemodynamic stability of using virtual reality immersion in adult patients undergoing Dacryocystorhinostomy (DCR) operation under general anesthesia and to compare its effect to that of using Midazolam as a premedication.",[152,153,154,28,155],"Anxiolytic Effect","Virtual Reality Immersion","Midazolam","Dacryocystorhinostomy","2025-06-25",{"date":158,"type":37},"2025-07-03",{"date":160,"type":37},"2025-06-01",{"date":162,"type":21},"2025-12-30",{"name":164,"class":71},"Cairo University",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":109,"sex":16,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":45},"100567711","phase-3-premedication-on-post-endodontic-pain-100567711","NCT06671743","Premedication on Post-endodontic Pain","Effect of Premedication on Post-endodontic Pain in Patients With Symptomatic Irreversible Pulpitis, a Triple-blinded Randomized Control Trial","Inclusion Criteria:\n\n* Eligibility for root canal treatment Patients diagnosed with symptomatic irreversible pulpitis with normal apical tissue in mandibular molars\n\nExclusion Criteria:\n\n* • Patient under any medication or analgesic intake for pain management.\n\n  * Patients with any systemic health issues\n  * Patient allergies to trypsin-chymotrypsin, ibuprofen, and paracetamol\n  * Pregnancy.\n  * Non-restorable teeth.\n  * Immature roots.\n  * Calcifications.\n  * Resorptions.","20 Years","50 Years",{"count":175,"type":21},48,[177],"PHASE3","The goal of this clinical trial is to compare the efficacy of preoperative administration of alpha-chemo-trypsin, ibuprofen, and acetaminophen in managing post-endodontic pain in patients with symptomatic irreversible pulpitis. The main question it aims to answer is:\n\nWhat is the efficacy of preoperative administration of alpha-chemo-trypsin, ibuprofen, and acetaminophen in managing post-endodontic pain in patients with symptomatic irreversible pulpitis? Participants will undergo root canal treatment after premedication. Researchers will compare \\[alpha-chemo-trypsin, ibuprofen, and acetaminophen\\] to see the intensity of post-endodontic pain.",[28],"2024-11-01",{"date":182,"type":37},"2024-11-04",{"date":184,"type":37},"2024-09-01",{"date":186,"type":21},"2026-11-01",{"name":188,"class":71},"Gulf Medical University"]